Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700529 · ClinicalTrials.gov registry record · Phase 2
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
A Phase 2 study of Lymphedema, sponsored by Eiger BioPharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 4
- Study locations
NCT02700529 is a Phase 2 study of Lymphedema that has completed, run by Eiger BioPharmaceuticals. The registered enrollment target is 54 participants, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02700529, a Phase 2 study of Lymphedema, has completed, sponsored by Eiger BioPharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 4
- Study locations
Study Summary
This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema.
Conditions Studied
Interventions
- OTHER placebo
- DRUG ubenimex
Study Locations (4)
California
- Stanford University - Stanford
Florida
- Orlando Health, Inc. - Orlando
Ohio
- The Ohio State University Wexner Medical Center James Cancer Hospital - Columbus
New South Wales
- Macquarie University Hospital (MUH) - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700529
The ClinicalTrials.gov registry entry for NCT02700529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The listed sponsor is Eiger BioPharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02700529 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT02700529 about?
NCT02700529 is a clinical study titled "Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)". This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema.
What is the current status of trial NCT02700529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2016-06. Estimated completion is 2019-02.
What conditions does trial NCT02700529 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT02700529?
The interventions under investigation include: placebo (OTHER), ubenimex (DRUG).
Who is sponsoring clinical trial NCT02700529?
This trial is sponsored by Eiger BioPharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700529 being conducted?
This trial has 4 study locations across California, Florida, Ohio, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
COMPLETED · Phase 2
-
Pycnogenol for the Treatment of Lymphedema
COMPLETED · Phase 2
-
Lymphedema Surveillance Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.